Target
Matrix metalloproteinase-25
Ligand
BDBM50305842
Substrate
n/a
Meas. Tech.
ChEMBL_605237 (CHEMBL1069317)
Ki
>25000±n/a nM
Citation
 Schnute, MEO'Brien, PMNahra, JMorris, MHoward Roark, WHanau, CERuminski, PGScholten, JAFletcher, TRHamper, BCCarroll, JNPatt, WCShieh, HSCollins, BPavlovsky, AGPalmquist, KEAston, KWHitchcock, JRogers, MDMcDonald, JJohnson, ARMunie, GEWittwer, AJMan, CFSettle, SLNemirovskiy, OVickery, LEAgawal, ADyer, RDSunyer, T Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett 20:576-80 (2010) [PubMed]  Article 
Target
Name:
Matrix metalloproteinase-25
Synonyms:
Leukolysin | MMP-25 | MMP20 | MMP25 | MMP25_HUMAN | MMPL1 | MT-MMP 6 | MT6-MMP | MT6MMP | MTMMP6 | Matrix metalloproteinase-25 | Membrane-type matrix metalloproteinase 6 | Membrane-type-6 matrix metalloproteinase | Membrane-type-6 matrix metalloproteinase (MT6-MMP)
Type:
Protein
Mol. Mass.:
62564.84
Organism:
Homo sapiens (Human)
Description:
Q9NPA2
Residue:
562
Sequence:
MRLRLRLLALLLLLLAPPARAPKPSAQDVSLGVDWLTRYGYLPPPHPAQAQLQSPEKLRDAIKVMQRFAGLPETGRMDPGTVATMRKPRCSLPDVLGVAGLVRRRRRYALSGSVWKKRTLTWRVRSFPQSSQLSQETVRVLMSYALMAWGMESGLTFHEVDSPQGQEPDILIDFARAFHQDSYPFDGLGGTLAHAFFPGEHPISGDTHFDDEETWTFGSKDGEGTDLFAVAVHEFGHALGLGHSSAPNSIMRPFYQGPVGDPDKYRLSQDDRDGLQQLYGKAPQTPYDKPTRKPLAPPPQPPASPTHSPSFPIPDRCEGNFDAIANIRGETFFFKGPWFWRLQPSGQLVSPRPARLHRFWEGLPAQVRVVQAAYARHRDGRILLFSGPQFWVFQDRQLEGGARPLTELGLPPGEEVDAVFSWPQNGKTYLVRGRQYWRYDEAAARPDPGYPRDLSLWEGAPPSPDDVTVSNAGDTYFFKGAHYWRFPKNSIKTEPDAPQPMGPNWLDCPAPSSGPRAPRPPKATPVSETCDCQCELNQAAGRWPAPIPLLLLPLLVGGVASR
  
Inhibitor
Name:
BDBM50305842
Synonyms:
CHEMBL603656 | trans-4-((5-(2-(4-fluorobenzylcarbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylic acid
Type:
Small organic molecule
Emp. Form.:
C23H25FN6O3
Mol. Mass.:
452.4814
SMILES:
Cc1cc(cc(n1)C(=O)NCc1ccc(F)cc1)-c1nnn(C[C@H]2CC[C@@H](CC2)C(O)=O)n1 |r,wU:26.31,wD:23.24,(30.11,-12.24,;29.32,-10.92,;30.07,-9.57,;29.28,-8.26,;27.74,-8.27,;26.98,-9.62,;27.77,-10.94,;25.44,-9.64,;24.69,-10.98,;24.66,-8.31,;23.12,-8.33,;22.33,-7.01,;23.08,-5.67,;22.3,-4.34,;20.75,-4.36,;19.97,-3.04,;20,-5.72,;20.79,-7.03,;30.03,-6.91,;29.39,-5.51,;30.52,-4.46,;31.87,-5.21,;33.27,-4.57,;34.61,-5.32,;34.63,-6.85,;35.98,-7.6,;37.3,-6.81,;37.27,-5.26,;35.93,-4.52,;38.65,-7.56,;38.68,-9.1,;39.97,-6.77,;31.57,-6.73,)|
Structure:
Search PDB for entries with ligand similarity: